182 related articles for article (PubMed ID: 24667567)
1. Testing of potential glycan-based heparanase inhibitors in a fluorescence activity assay using either bacterial heparinase II or human heparanase.
Schoenfeld AK; Vierfuß S; Lühn S; Alban S
J Pharm Biomed Anal; 2014 Jul; 95():130-8. PubMed ID: 24667567
[TBL] [Abstract][Full Text] [Related]
2. Development of both colorimetric and fluorescence heparinase activity assays using fondaparinux as substrate.
Schiemann S; Lühn S; Alban S
Anal Biochem; 2012 Aug; 427(1):82-90. PubMed ID: 22579846
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues.
Marchetti D; Reiland J; Erwin B; Roy M
Int J Cancer; 2003 Mar; 104(2):167-74. PubMed ID: 12569571
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological profiles of animal- and nonanimal-derived sulfated polysaccharides--comparison of unfractionated heparin, the semisynthetic glucan sulfate PS3, and the sulfated polysaccharide fraction isolated from Delesseria sanguinea.
Groth I; Grünewald N; Alban S
Glycobiology; 2009 Apr; 19(4):408-17. PubMed ID: 19106233
[TBL] [Abstract][Full Text] [Related]
5. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity.
Parish CR; Freeman C; Brown KJ; Francis DJ; Cowden WB
Cancer Res; 1999 Jul; 59(14):3433-41. PubMed ID: 10416607
[TBL] [Abstract][Full Text] [Related]
6. 1H NMR spectroscopic studies establish that heparanase is a retaining glycosidase.
Wilson JC; Laloo AE; Singh S; Ferro V
Biochem Biophys Res Commun; 2014 Jan; 443(1):185-8. PubMed ID: 24291708
[TBL] [Abstract][Full Text] [Related]
7. Development of new methods for determining the heparanase enzymatic activity.
Melo CM; Tersariol IL; Nader HB; Pinhal MA; Lima MA
Carbohydr Res; 2015 Aug; 412():66-70. PubMed ID: 26062789
[TBL] [Abstract][Full Text] [Related]
8. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting.
Naggi A; Casu B; Perez M; Torri G; Cassinelli G; Penco S; Pisano C; Giannini G; Ishai-Michaeli R; Vlodavsky I
J Biol Chem; 2005 Apr; 280(13):12103-13. PubMed ID: 15647251
[TBL] [Abstract][Full Text] [Related]
9. Structural requirements for inhibition of melanoma lung colonization by heparanase inhibiting species of heparin.
Bitan M; Mohsen M; Levi E; Wygoda MR; Miao HQ; Lider O; Svahn CM; Ekre HP; Ishai-Michaeli R; Bar-Shavit R
Isr J Med Sci; 1995; 31(2-3):106-18. PubMed ID: 7744578
[TBL] [Abstract][Full Text] [Related]
10. Murine macrophage heparanase: inhibition and comparison with metastatic tumor cells.
Savion N; Disatnik MH; Nevo Z
J Cell Physiol; 1987 Jan; 130(1):77-84. PubMed ID: 3805131
[TBL] [Abstract][Full Text] [Related]
11. Development of a colorimetric assay for heparanase activity suitable for kinetic analysis and inhibitor screening.
Hammond E; Li CP; Ferro V
Anal Biochem; 2010 Jan; 396(1):112-6. PubMed ID: 19748475
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species.
Bar-Ner M; Eldor A; Wasserman L; Matzner Y; Cohen IR; Fuks Z; Vlodavsky I
Blood; 1987 Aug; 70(2):551-7. PubMed ID: 2955820
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in the discovery of heparanase inhibitors as anti-cancer agents.
Jia L; Ma S
Eur J Med Chem; 2016 Oct; 121():209-220. PubMed ID: 27240275
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of PMN-elastase activity by semisynthetic glucan sulfates.
Becker M; Franz G; Alban S
Thromb Haemost; 2003 May; 89(5):915-25. PubMed ID: 12719790
[TBL] [Abstract][Full Text] [Related]
15. The influence of various structural parameters of semisynthetic sulfated polysaccharides on the P-selectin inhibitory capacity.
Fritzsche J; Alban S; Ludwig RJ; Rubant S; Boehncke WH; Schumacher G; Bendas G
Biochem Pharmacol; 2006 Aug; 72(4):474-85. PubMed ID: 16780802
[TBL] [Abstract][Full Text] [Related]
16. Suramin inhibits hepatic tissue damage in hepatocellular carcinoma through deactivation of heparanase enzyme.
Tayel A; Abd El Galil KH; Ebrahim MA; Ibrahim AS; El-Gayar AM; Al-Gayyar MM
Eur J Pharmacol; 2014 Apr; 728():151-60. PubMed ID: 24530413
[TBL] [Abstract][Full Text] [Related]
17. Oligomannurarate sulfate, a novel heparanase inhibitor simultaneously targeting basic fibroblast growth factor, combats tumor angiogenesis and metastasis.
Zhao H; Liu H; Chen Y; Xin X; Li J; Hou Y; Zhang Z; Zhang X; Xie C; Geng M; Ding J
Cancer Res; 2006 Sep; 66(17):8779-87. PubMed ID: 16951194
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of tumor metastasis by heparanase inhibiting species of heparin.
Vlodavsky I; Mohsen M; Lider O; Svahn CM; Ekre HP; Vigoda M; Ishai-Michaeli R; Peretz T
Invasion Metastasis; 1994-1995; 14(1-6):290-302. PubMed ID: 7657522
[TBL] [Abstract][Full Text] [Related]
19. Suramin. A potent inhibitor of melanoma heparanase and invasion.
Nakajima M; DeChavigny A; Johnson CE; Hamada J; Stein CA; Nicolson GL
J Biol Chem; 1991 May; 266(15):9661-6. PubMed ID: 2033058
[TBL] [Abstract][Full Text] [Related]
20. Computational analyses of the catalytic and heparin-binding sites and their interactions with glycosaminoglycans in glycoside hydrolase family 79 endo-β-D-glucuronidase (heparanase).
Gandhi NS; Freeman C; Parish CR; Mancera RL
Glycobiology; 2012 Jan; 22(1):35-55. PubMed ID: 21746763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
